APO Research
Talk to an analyst

APO RESEARCH · REPORT

AI Pharma

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global AI Pharma Industry Growth and Trends Forecast to 2032

2 January 2026124 pages

Choose your research edition.

Industry ResearchAI Pharma Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal AI Pharma Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal AI Pharma Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal AI Pharma Market Outlook and Growth Opportunities 2026212 pages · $4,250 USDMarket Analysis & ForecastGlobal AI Pharma Market Analysis and Forecast 2026-2032218 pages · $4,950 USD

Market perspective

According to APO Research, the global AI Pharma market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for AI Pharma is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for AI Pharma is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for AI Pharma is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the AI Pharma market include Recursion, Insilico Medicine, Exscientia, BenevolentAI, Atomwise, Roivant Sciences, Schrödinger, Lantern Pharma and XtalPi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global AI Pharma market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The AI Pharma market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global AI Pharma market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to AI Pharma.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global AI Pharma market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

AI Pharma Market by Company

Recursion

Insilico Medicine

Exscientia

BenevolentAI

Atomwise

Roivant Sciences

Schrödinger

Lantern Pharma

XtalPi

Landos Biopharma

Relay Therapeutics

Accutar Biotech

Deep Genomics

Oncocross

AI Therapeutics

BioMap

METiS Pharmaceuticals

NeoX Biotech

StoneWise

Deep Intelligent Pharma

Gigaceuticals

Chemical.AI

Artivila

Galixir

Xbiome

AI Pharma Segment by Type

Self-developed Oipeline

Contract Research Organization (CRO)

Other

AI Pharma Segment by Application

Preclinical Stage (Optimization of Lead Compounds, etc.)

Clinical Trial Phase (Predicting Treatment Outcome, etc.)

AI Pharma Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global AI Pharma market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of AI Pharma and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of AI Pharma.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of AI Pharma companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global AI Pharma Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global AI Pharma Market Size by Region (2021-2026) & (US$ Million) Table 3. Global AI Pharma Market Share by Region (2021-2026) Table 4. Global AI Pharma Market Size by Region (2027-2032) & (US$ Million) Table 5. Global AI Pharma Market Share by Region (2027-2032) Table 6. Global AI Pharma Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global AI Pharma Market Size by Type (2021-2026) & (US$ Million) Table 8. Global AI Pharma Market Size Share by Type (2021-2026) Table 9. Global AI Pharma Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global AI Pharma Market Size Share Forecasted by Type (2027-2032) Table 11. North America AI Pharma Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America AI Pharma Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe AI Pharma Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe AI Pharma Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific AI Pharma Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific AI Pharma Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America AI Pharma Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America AI Pharma Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa AI Pharma Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa AI Pharma Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global AI Pharma Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global AI Pharma Market Size by Application (2021-2026) & (US$ Million) Table 23. Global AI Pharma Market Size Share by Application (2021-2026) Table 24. Global AI Pharma Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global AI Pharma Market Size Share Forecasted by Application (2027-2032) Table 26. North America AI Pharma Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America AI Pharma Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe AI Pharma Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe AI Pharma Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific AI Pharma Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific AI Pharma Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America AI Pharma Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America AI Pharma Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa AI Pharma Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa AI Pharma Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. AI Pharma Industry Trends Table 37. AI Pharma Industry Drivers Table 38. AI Pharma Industry Opportunities and Challenges Table 39. AI Pharma Industry Restraints Table 40. Global AI Pharma Revenue by Company (US$ Million) & (2021-2026) Table 41. Global AI Pharma Revenue Market Share by Company (2021-2026) Table 42. Global AI Pharma Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global AI Pharma Key Company Headquarters & Area Served Table 44. Global AI Pharma Company, Product Type & Application Table 45. Global AI Pharma Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global AI Pharma by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Recursion Company Information Table 49. Recursion Business Overview Table 50. Recursion AI Pharma Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Recursion AI Pharma Product Portfolio Table 52. Recursion Recent Development Table 53. Insilico Medicine Company Information Table 54. Insilico Medicine Business Overview Table 55. Insilico Medicine AI Pharma Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Insilico Medicine AI Pharma Product Portfolio Table 57. Insilico Medicine Recent Development Table 58. Exscientia Company Information Table 59. Exscientia Business Overview Table 60. Exscientia AI Pharma Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Exscientia AI Pharma Product Portfolio Table 62. Exscientia Recent Development Table 63. BenevolentAI Company Information Table 64. BenevolentAI Business Overview Table 65. BenevolentAI AI Pharma Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. BenevolentAI AI Pharma Product Portfolio Table 67. BenevolentAI Recent Development Table 68. Atomwise Company Information Table 69. Atomwise Business Overview Table 70. Atomwise AI Pharma Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Atomwise AI Pharma Product Portfolio Table 72. Atomwise Recent Development Table 73. Roivant Sciences Company Information Table 74. Roivant Sciences Business Overview Table 75. Roivant Sciences AI Pharma Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Roivant Sciences AI Pharma Product Portfolio Table 77. Roivant Sciences Recent Development Table 78. Schrödinger Company Information Table 79. Schrödinger Business Overview Table 80. Schrödinger AI Pharma Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Schrödinger AI Pharma Product Portfolio Table 82. Schrödinger Recent Development Table 83. Lantern Pharma Company Information Table 84. Lantern Pharma Business Overview Table 85. Lantern Pharma AI Pharma Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Lantern Pharma AI Pharma Product Portfolio Table 87. Lantern Pharma Recent Development Table 88. XtalPi Company Information Table 89. XtalPi Business Overview Table 90. XtalPi AI Pharma Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. XtalPi AI Pharma Product Portfolio Table 92. XtalPi Recent Development Table 93. Landos Biopharma Company Information Table 94. Landos Biopharma Business Overview Table 95. Landos Biopharma AI Pharma Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Landos Biopharma AI Pharma Product Portfolio Table 97. Landos Biopharma Recent Development Table 98. Relay Therapeutics Company Information Table 99. Relay Therapeutics Business Overview Table 100. Relay Therapeutics AI Pharma Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Relay Therapeutics AI Pharma Product Portfolio Table 102. Relay Therapeutics Recent Development Table 103. Accutar Biotech Company Information Table 104. Accutar Biotech Business Overview Table 105. Accutar Biotech AI Pharma Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Accutar Biotech AI Pharma Product Portfolio Table 107. Accutar Biotech Recent Development Table 108. Deep Genomics Company Information Table 109. Deep Genomics Business Overview Table 110. Deep Genomics AI Pharma Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Deep Genomics AI Pharma Product Portfolio Table 112. Deep Genomics Recent Development Table 113. Oncocross Company Information Table 114. Oncocross Business Overview Table 115. Oncocross AI Pharma Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Oncocross AI Pharma Product Portfolio Table 117. Oncocross Recent Development Table 118. AI Therapeutics Company Information Table 119. AI Therapeutics Business Overview Table 120. AI Therapeutics AI Pharma Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. AI Therapeutics AI Pharma Product Portfolio Table 122. AI Therapeutics Recent Development Table 123. BioMap Company Information Table 124. BioMap Business Overview Table 125. BioMap AI Pharma Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. BioMap AI Pharma Product Portfolio Table 127. BioMap Recent Development Table 128. METiS Pharmaceuticals Company Information Table 129. METiS Pharmaceuticals Business Overview Table 130. METiS Pharmaceuticals AI Pharma Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. METiS Pharmaceuticals AI Pharma Product Portfolio Table 132. METiS Pharmaceuticals Recent Development Table 133. NeoX Biotech Company Information Table 134. NeoX Biotech Business Overview Table 135. NeoX Biotech AI Pharma Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 136. NeoX Biotech AI Pharma Product Portfolio Table 137. NeoX Biotech Recent Development Table 138. StoneWise Company Information Table 139. StoneWise Business Overview Table 140. StoneWise AI Pharma Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 141. StoneWise AI Pharma Product Portfolio Table 142. StoneWise Recent Development Table 143. Deep Intelligent Pharma Company Information Table 144. Deep Intelligent Pharma Business Overview Table 145. Deep Intelligent Pharma AI Pharma Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 146. Deep Intelligent Pharma AI Pharma Product Portfolio Table 147. Deep Intelligent Pharma Recent Development Table 148. Gigaceuticals Company Information Table 149. Gigaceuticals Business Overview Table 150. Gigaceuticals AI Pharma Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 151. Gigaceuticals AI Pharma Product Portfolio Table 152. Gigaceuticals Recent Development Table 153. Chemical.AI Company Information Table 154. Chemical.AI Business Overview Table 155. Chemical.AI AI Pharma Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 156. Chemical.AI AI Pharma Product Portfolio Table 157. Chemical.AI Recent Development Table 158. Artivila Company Information Table 159. Artivila Business Overview Table 160. Artivila AI Pharma Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 161. Artivila AI Pharma Product Portfolio Table 162. Artivila Recent Development Table 163. Galixir Company Information Table 164. Galixir Business Overview Table 165. Galixir AI Pharma Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 166. Galixir AI Pharma Product Portfolio Table 167. Galixir Recent Development Table 168. Xbiome Company Information Table 169. Xbiome Business Overview Table 170. Xbiome AI Pharma Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 171. Xbiome AI Pharma Product Portfolio Table 172. Xbiome Recent Development Table 173. North America AI Pharma Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 174. North America AI Pharma Market Size by Country (2021-2026) & (US$ Million) Table 175. North America AI Pharma Market Share by Country (2021-2026) Table 176. North America AI Pharma Market Size Forecast by Country (2027-2032) & (US$ Million) Table 177. North America AI Pharma Market Share Forecast by Country (2027-2032) Table 178. Europe AI Pharma Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 179. Europe AI Pharma Market Size by Country (2021-2026) & (US$ Million) Table 180. Europe AI Pharma Market Share by Country (2021-2026) Table 181. Europe AI Pharma Market Size Forecast by Country (2027-2032) & (US$ Million) Table 182. Europe AI Pharma Market Share Forecast by Country (2027-2032) Table 183. Asia-Pacific AI Pharma Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 184. Asia-Pacific AI Pharma Market Size by Country (2021-2026) & (US$ Million) Table 185. Asia-Pacific AI Pharma Market Share by Country (2021-2026) Table 186. Asia-Pacific AI Pharma Market Size Forecast by Country (2027-2032) & (US$ Million) Table 187. Asia-Pacific AI Pharma Market Share Forecast by Country (2027-2032) Table 188. Latin America AI Pharma Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 189. Latin America AI Pharma Market Size by Country (2021-2026) & (US$ Million) Table 190. Latin America AI Pharma Market Share by Country (2021-2026) Table 191. Latin America AI Pharma Market Size Forecast by Country (2027-2032) & (US$ Million) Table 192. Latin America AI Pharma Market Share Forecast by Country (2027-2032) Table 193. Middle East & Africa AI Pharma Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 194. Middle East & Africa AI Pharma Market Size by Country (2021-2026) & (US$ Million) Table 195. Middle East & Africa AI Pharma Market Share by Country (2021-2026) Table 196. Middle East & Africa AI Pharma Market Size Forecast by Country (2027-2032) & (US$ Million) Table 197. Middle East & Africa AI Pharma Market Share Forecast by Country (2027-2032) Table 198. Research Programs/Design for This Report Table 199. Authors List of This Report Table 200. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. AI Pharma Product Image Figure 3. Global AI Pharma Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global AI Pharma Market Size (2021-2032) & (US$ Million) Figure 5. Global AI Pharma Market Share by Region: 2025 VS 2032 Figure 6. Global AI Pharma Market Share by Region (2021-2032) Figure 7. North America AI Pharma Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe AI Pharma Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific AI Pharma Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America AI Pharma Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa AI Pharma Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Self-developed Oipeline Image Figure 13. Global Self-developed Oipeline Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Contract Research Organization (CRO) Image Figure 15. Global Contract Research Organization (CRO) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Other Image Figure 17. Global Other Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Global AI Pharma Market Size Overview by Type (2021-2032) & (US$ Million) Figure 19. Global AI Pharma Market Share by Type 2025 VS 2032 Figure 20. North America AI Pharma Market Size Share by Type (2021-2032) Figure 21. Europe AI Pharma Market Size Share by Type (2021-2032) Figure 22. Asia-Pacific AI Pharma Market Size Share by Type (2021-2032) Figure 23. Latin America AI Pharma Market Size Share by Type (2021-2032) Figure 24. Middle East and Africa AI Pharma Market Size Share by Type (2021-2032) Figure 25. Preclinical Stage (Optimization of Lead Compounds, etc.) Image Figure 26. Global Preclinical Stage (Optimization of Lead Compounds, etc.) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Clinical Trial Phase (Predicting Treatment Outcome, etc.) Image Figure 28. Global Clinical Trial Phase (Predicting Treatment Outcome, etc.) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Global AI Pharma Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global AI Pharma Market Share by Application 2025 VS 2032 Figure 31. North America AI Pharma Market Size Share by Application (2021-2032) Figure 32. Europe AI Pharma Market Size Share by Application (2021-2032) Figure 33. Asia-Pacific AI Pharma Market Size Share by Application (2021-2032) Figure 34. Latin America AI Pharma Market Size Share by Application (2021-2032) Figure 35. Middle East and Africa AI Pharma Market Size Share by Application (2021-2032) Figure 36. Global Top 5 and 10 AI Pharma Players Market Share by Revenue in 2025 Figure 37. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 38. North America AI Pharma Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 39. North America AI Pharma Market Share by Country: 2021 VS 2025 VS 2032 Figure 40. North America AI Pharma Market Share by Country (2021-2032) Figure 41. Europe AI Pharma Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 42. Europe AI Pharma Market Share by Country: 2021 VS 2025 VS 2032 Figure 43. Europe AI Pharma Market Share by Country (2021-2032) Figure 44. Asia-Pacific AI Pharma Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 45. Asia-Pacific AI Pharma Market Share by Country: 2021 VS 2025 VS 2032 Figure 46. Asia-Pacific AI Pharma Market Share by Country (2021-2032) Figure 47. Latin America AI Pharma Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Latin America AI Pharma Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Latin America AI Pharma Market Share by Country (2021-2032) Figure 50. Middle East & Africa AI Pharma Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 51. Middle East & Africa AI Pharma Market Share by Country: 2021 VS 2025 VS 2032 Figure 52. Middle East & Africa AI Pharma Market Share by Country (2021-2032) Figure 53. Years Considered Figure 54. Research Process Figure 55. Key Executives Interviewed

Scope & coverage.

Types
  • Self-developed Oipeline
  • Contract Research Organization (CRO)
  • Other
Applications
  • Preclinical Stage (Optimization of Lead Compounds, etc.)
  • Clinical Trial Phase (Predicting Treatment Outcome, etc.)
Companies covered
  • Recursion
  • Insilico Medicine
  • Exscientia
  • BenevolentAI
  • Atomwise
  • Roivant Sciences
  • Schrödinger
  • Lantern Pharma
  • XtalPi
  • Landos Biopharma
  • Relay Therapeutics
  • Accutar Biotech
  • Deep Genomics
  • Oncocross
  • AI Therapeutics
  • BioMap
  • METiS Pharmaceuticals
  • NeoX Biotech
  • StoneWise
  • Deep Intelligent Pharma
  • Gigaceuticals
  • Chemical.AI
  • Artivila
  • Galixir
  • Xbiome

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global AI Pharma Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global AI Pharma Market Size by Region (2021-2032)
  5. 1.4.1 Global AI Pharma Market Size by Region (2021-2026)
  6. 1.4.2 Global AI Pharma Market Size by Region (2027-2032)
  7. 1.5 Key Regions AI Pharma Market Size (2021-2032)
  8. 1.5.1 North America AI Pharma Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe AI Pharma Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific AI Pharma Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America AI Pharma Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa AI Pharma Market Size Growth Rate (2021-2032)
2 AI Pharma Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Self-developed Oipeline
  3. 2.1.2 Contract Research Organization (CRO)
  4. 2.1.3 Other
  5. 2.2 Global AI Pharma Market Size by Type
  6. 2.2.1 Global AI Pharma Market Size Overview by Type (2021-2032)
  7. 2.2.2 Global AI Pharma Historic Market Size Review by Type (2021-2026)
  8. 2.2.3 Global AI Pharma Market Size Forecasted by Type (2027-2032)
  9. 2.3 Global AI Pharma Market Size by Regions
  10. 2.3.1 North America AI Pharma Market Size Breakdown by Type (2021-2026)
  11. 2.3.2 Europe AI Pharma Market Size Breakdown by Type (2021-2026)
  12. 2.3.3 Asia-Pacific AI Pharma Market Size Breakdown by Type (2021-2026)
  13. 2.3.4 South America AI Pharma Market Size Breakdown by Type (2021-2026)
  14. 2.3.5 Middle East and Africa AI Pharma Market Size Breakdown by Type (2021-2026)
3 AI Pharma Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Preclinical Stage (Optimization of Lead Compounds, etc.)
  3. 3.1.2 Clinical Trial Phase (Predicting Treatment Outcome, etc.)
  4. 3.2 Global AI Pharma Market Size by Application
  5. 3.2.1 Global AI Pharma Market Size Overview by Application (2021-2032)
  6. 3.2.2 Global AI Pharma Historic Market Size Review by Application (2021-2026)
  7. 3.2.3 Global AI Pharma Market Size Forecasted by Application (2027-2032)
  8. 3.3 Global AI Pharma Market Size by Regions
  9. 3.3.1 North America AI Pharma Market Size Breakdown by Application (2021-2026)
  10. 3.3.2 Europe AI Pharma Market Size Breakdown by Application (2021-2026)
  11. 3.3.3 Asia-Pacific AI Pharma Market Size Breakdown by Application (2021-2026)
  12. 3.3.4 South America AI Pharma Market Size Breakdown by Application (2021-2026)
  13. 3.3.5 Middle East and Africa AI Pharma Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 AI Pharma Industry Trends
  2. 4.2 AI Pharma Industry Drivers
  3. 4.3 AI Pharma Industry Opportunities and Challenges
  4. 4.4 AI Pharma Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by AI Pharma Revenue (2021-2026)
  2. 5.2 Global AI Pharma Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global AI Pharma Key Company Headquarters & Area Served
  4. 5.4 Global AI Pharma Company, Product Type & Application
  5. 5.5 Global AI Pharma Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global AI Pharma Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 AI Pharma Players Market Share by Revenue in 2025
  9. 5.6.3 2025 AI Pharma Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Recursion
  2. 6.1.1 Recursion Company Information
  3. 6.1.2 Recursion Business Overview
  4. 6.1.3 Recursion AI Pharma Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Recursion AI Pharma Product Portfolio
  6. 6.1.5 Recursion Recent Developments
  7. 6.2 Insilico Medicine
  8. 6.2.1 Insilico Medicine Company Information
  9. 6.2.2 Insilico Medicine Business Overview
  10. 6.2.3 Insilico Medicine AI Pharma Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Insilico Medicine AI Pharma Product Portfolio
  12. 6.2.5 Insilico Medicine Recent Developments
  13. 6.3 Exscientia
  14. 6.3.1 Exscientia Company Information
  15. 6.3.2 Exscientia Business Overview
  16. 6.3.3 Exscientia AI Pharma Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Exscientia AI Pharma Product Portfolio
  18. 6.3.5 Exscientia Recent Developments
  19. 6.4 BenevolentAI
  20. 6.4.1 BenevolentAI Company Information
  21. 6.4.2 BenevolentAI Business Overview
  22. 6.4.3 BenevolentAI AI Pharma Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 BenevolentAI AI Pharma Product Portfolio
  24. 6.4.5 BenevolentAI Recent Developments
  25. 6.5 Atomwise
  26. 6.5.1 Atomwise Company Information
  27. 6.5.2 Atomwise Business Overview
  28. 6.5.3 Atomwise AI Pharma Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Atomwise AI Pharma Product Portfolio
  30. 6.5.5 Atomwise Recent Developments
  31. 6.6 Roivant Sciences
  32. 6.6.1 Roivant Sciences Company Information
  33. 6.6.2 Roivant Sciences Business Overview
  34. 6.6.3 Roivant Sciences AI Pharma Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Roivant Sciences AI Pharma Product Portfolio
  36. 6.6.5 Roivant Sciences Recent Developments
  37. 6.7 Schrödinger
  38. 6.7.1 Schrödinger Company Information
  39. 6.7.2 Schrödinger Business Overview
  40. 6.7.3 Schrödinger AI Pharma Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Schrödinger AI Pharma Product Portfolio
  42. 6.7.5 Schrödinger Recent Developments
  43. 6.8 Lantern Pharma
  44. 6.8.1 Lantern Pharma Company Information
  45. 6.8.2 Lantern Pharma Business Overview
  46. 6.8.3 Lantern Pharma AI Pharma Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Lantern Pharma AI Pharma Product Portfolio
  48. 6.8.5 Lantern Pharma Recent Developments
  49. 6.9 XtalPi
  50. 6.9.1 XtalPi Company Information
  51. 6.9.2 XtalPi Business Overview
  52. 6.9.3 XtalPi AI Pharma Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 XtalPi AI Pharma Product Portfolio
  54. 6.9.5 XtalPi Recent Developments
  55. 6.10 Landos Biopharma
  56. 6.10.1 Landos Biopharma Company Information
  57. 6.10.2 Landos Biopharma Business Overview
  58. 6.10.3 Landos Biopharma AI Pharma Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Landos Biopharma AI Pharma Product Portfolio
  60. 6.10.5 Landos Biopharma Recent Developments
  61. 6.11 Relay Therapeutics
  62. 6.11.1 Relay Therapeutics Company Information
  63. 6.11.2 Relay Therapeutics Business Overview
  64. 6.11.3 Relay Therapeutics AI Pharma Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Relay Therapeutics AI Pharma Product Portfolio
  66. 6.11.5 Relay Therapeutics Recent Developments
  67. 6.12 Accutar Biotech
  68. 6.12.1 Accutar Biotech Company Information
  69. 6.12.2 Accutar Biotech Business Overview
  70. 6.12.3 Accutar Biotech AI Pharma Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Accutar Biotech AI Pharma Product Portfolio
  72. 6.12.5 Accutar Biotech Recent Developments
  73. 6.13 Deep Genomics
  74. 6.13.1 Deep Genomics Company Information
  75. 6.13.2 Deep Genomics Business Overview
  76. 6.13.3 Deep Genomics AI Pharma Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Deep Genomics AI Pharma Product Portfolio
  78. 6.13.5 Deep Genomics Recent Developments
  79. 6.14 Oncocross
  80. 6.14.1 Oncocross Company Information
  81. 6.14.2 Oncocross Business Overview
  82. 6.14.3 Oncocross AI Pharma Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Oncocross AI Pharma Product Portfolio
  84. 6.14.5 Oncocross Recent Developments
  85. 6.15 AI Therapeutics
  86. 6.15.1 AI Therapeutics Company Information
  87. 6.15.2 AI Therapeutics Business Overview
  88. 6.15.3 AI Therapeutics AI Pharma Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 AI Therapeutics AI Pharma Product Portfolio
  90. 6.15.5 AI Therapeutics Recent Developments
  91. 6.16 BioMap
  92. 6.16.1 BioMap Company Information
  93. 6.16.2 BioMap Business Overview
  94. 6.16.3 BioMap AI Pharma Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 BioMap AI Pharma Product Portfolio
  96. 6.16.5 BioMap Recent Developments
  97. 6.17 METiS Pharmaceuticals
  98. 6.17.1 METiS Pharmaceuticals Company Information
  99. 6.17.2 METiS Pharmaceuticals Business Overview
  100. 6.17.3 METiS Pharmaceuticals AI Pharma Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 METiS Pharmaceuticals AI Pharma Product Portfolio
  102. 6.17.5 METiS Pharmaceuticals Recent Developments
  103. 6.18 NeoX Biotech
  104. 6.18.1 NeoX Biotech Company Information
  105. 6.18.2 NeoX Biotech Business Overview
  106. 6.18.3 NeoX Biotech AI Pharma Revenue, Global Share and Gross Margin (2021-2026)
  107. 6.18.4 NeoX Biotech AI Pharma Product Portfolio
  108. 6.18.5 NeoX Biotech Recent Developments
  109. 6.19 StoneWise
  110. 6.19.1 StoneWise Company Information
  111. 6.19.2 StoneWise Business Overview
  112. 6.19.3 StoneWise AI Pharma Revenue, Global Share and Gross Margin (2021-2026)
  113. 6.19.4 StoneWise AI Pharma Product Portfolio
  114. 6.19.5 StoneWise Recent Developments
  115. 6.20 Deep Intelligent Pharma
  116. 6.20.1 Deep Intelligent Pharma Company Information
  117. 6.20.2 Deep Intelligent Pharma Business Overview
  118. 6.20.3 Deep Intelligent Pharma AI Pharma Revenue, Global Share and Gross Margin (2021-2026)
  119. 6.20.4 Deep Intelligent Pharma AI Pharma Product Portfolio
  120. 6.20.5 Deep Intelligent Pharma Recent Developments
  121. 6.21 Gigaceuticals
  122. 6.21.1 Gigaceuticals Company Information
  123. 6.21.2 Gigaceuticals Business Overview
  124. 6.21.3 Gigaceuticals AI Pharma Revenue, Global Share and Gross Margin (2021-2026)
  125. 6.21.4 Gigaceuticals AI Pharma Product Portfolio
  126. 6.21.5 Gigaceuticals Recent Developments
  127. 6.22 Chemical.AI
  128. 6.22.1 Chemical.AI Company Information
  129. 6.22.2 Chemical.AI Business Overview
  130. 6.22.3 Chemical.AI AI Pharma Revenue, Global Share and Gross Margin (2021-2026)
  131. 6.22.4 Chemical.AI AI Pharma Product Portfolio
  132. 6.22.5 Chemical.AI Recent Developments
  133. 6.23 Artivila
  134. 6.23.1 Artivila Company Information
  135. 6.23.2 Artivila Business Overview
  136. 6.23.3 Artivila AI Pharma Revenue, Global Share and Gross Margin (2021-2026)
  137. 6.23.4 Artivila AI Pharma Product Portfolio
  138. 6.23.5 Artivila Recent Developments
  139. 6.24 Galixir
  140. 6.24.1 Galixir Company Information
  141. 6.24.2 Galixir Business Overview
  142. 6.24.3 Galixir AI Pharma Revenue, Global Share and Gross Margin (2021-2026)
  143. 6.24.4 Galixir AI Pharma Product Portfolio
  144. 6.24.5 Galixir Recent Developments
  145. 6.25 Xbiome
  146. 6.25.1 Xbiome Company Information
  147. 6.25.2 Xbiome Business Overview
  148. 6.25.3 Xbiome AI Pharma Revenue, Global Share and Gross Margin (2021-2026)
  149. 6.25.4 Xbiome AI Pharma Product Portfolio
  150. 6.25.5 Xbiome Recent Developments
7 North America
  1. 7.1 North America AI Pharma Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America AI Pharma Market Size by Country (2021-2026)
  3. 7.3 North America AI Pharma Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe AI Pharma Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe AI Pharma Market Size by Country (2021-2026)
  3. 8.3 Europe AI Pharma Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific AI Pharma Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific AI Pharma Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific AI Pharma Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America AI Pharma Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America AI Pharma Market Size by Country (2021-2026)
  3. 10.3 South America AI Pharma Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa AI Pharma Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa AI Pharma Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa AI Pharma Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst